摘要号：APASL 2025-11271

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy for chronic hepatitis C patients with failed previous direct-acting antivirals treatment. 

索磷布韦/维帕他韦/伏西瑞韦（SOF/VEL/VOX）作为既往直接抗病毒药物治疗失败的慢性丙型肝炎患者挽救治疗的有效性和安全性

作者：Jie Xia

摘要号：APASL 2025-12655

Coblopasvir and sofosbuvir treatment for Chinese patients with chronic HCV infection is safe and efficacious: a real-world study. 

可洛派韦联合索磷布韦治疗中国慢性 HCV感染患者安全有效：一项真实世界的研究

作者：Aidi Ma

摘要号：APASL 2025-14933

12-week treatment of sofosbuvir/velpatasvir plus ribavirin and sofosbuvir/velpatasvir/voxilaprevir for HCV patients with GT3b and compensated cirrhosis: a multicenter, randomized, open-label study in China. 

作者：RUI HUANG

摘要号：APASL 2025-15052

Safety and Efficacy of Direct-acting Antiviral Agents Therapy in Patients with Liver Failure Complicated by HCV Infection. 

肝衰竭合并丙型肝炎病毒感染患者应用直接抗病毒药物治疗的安全性和有效性。

摘要号：APASL 2025-13293

The study of the risk of long - term adverse events in patients with hepatitis C after treatment with Direct - acting antivirals.

摘要号：APASL 2025-14458

Efficacy and Prognosis of Direct - Acting Antiviral Therapy in Chronic Hepatitis C–Related Decompensated Cirrhosis.

作者：Jianping Li

摘要号：APASL 2025-16187

Exploration of Strategies for Conducting Universal Hepatitis C Virus (HCV) Screening among the General Population in China. 

作者：Qiran Zhang

摘要号：APASL 2025-16742

Efficacy and safety of coblopasvir plus sofosbuvir treatment for Chinese patients with chronic HCV infection: a large - scale, multicenter retrospective study. 

作者：Fangfang WEI

摘要号：APASL 2025-15356

Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study.

作者：Stacey Scherbakovsky

摘要号：APASL 2025-16430

Study of overall survival and factors affecting outcomes in chronic hepatitis C patients undergoing liver transplantation: A single - centered cohort study.